GBA's "2021 Stock Phantasma"

Heaven just rang a doorbell. Everything is shrink wrapped no rodents got to it I gots me fried chicken & popovers! mashed potatoes and Mac n Cheese... Oh and did I mention glazed donuts>!!!!

Thank You California!
 
https://thefly.com/news.php?symbol=SURF#
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush 03/10
SURF
Wedbush analyst Robert Driscoll reiterates an Outperform rating on Surface Oncology with an $18 price target following the company's Q4 results. The analyst sees "upcoming value inflection points" over the next several months, with clinical updates for SRF617 and SRF388 expected in Q2. Given the "broad potential" of both lead programs, Surface shares offer a "highly favorable" risk/reward profile ahead of these readouts, Driscoll tells investors in a research note.
 
Surface Oncology reports Q4 EPS $1.56, consensus 22c 03/09 SURF Reports Q4 revenue $87.6M, consensus $34M. "The fourth quarter of 2020 was transformational for Surface. During this quarter, we provided encouraging clinical data from our lead candidates and validated our preclinical discovery capabilities with a second major outlicense agreement that provided the company with substantial financial flexibility for several years," said Rob Ross, M.D., incoming chief executive officer. "Today, we are also announcing another clinical trial collaboration further enabling rapid assessment of our lead product candidates in combination with pembrolizumab, focusing on patients with liver and kidney cancers. As we look forward into 2021, we are targeting ASCO in June to share additional clinical data on SRF617 and SRF388, and we will work with our partner, GSK, to advance SRF813 into the clinic."

$8.13 at time of Earn this looks good!>>>>

Van didn't you unearth this a ways back?
 
stonedinvestor said:
Surface Oncology reports Q4 EPS $1.56, consensus 22c 03/09 SURF Reports Q4 revenue $87.6M, consensus $34M. "The fourth quarter of 2020 was transformational for Surface. During this quarter, we provided encouraging clinical data from our lead candidates and validated our preclinical discovery capabilities with a second major outlicense agreement that provided the company with substantial financial flexibility for several years," said Rob Ross, M.D., incoming chief executive officer. "Today, we are also announcing another clinical trial collaboration further enabling rapid assessment of our lead product candidates in combination with pembrolizumab, focusing on patients with liver and kidney cancers. As we look forward into 2021, we are targeting ASCO in June to share additional clinical data on SRF617 and SRF388, and we will work with our partner, GSK, to advance SRF813 into the clinic."

$8.13 at time of Earn this looks good!>>>>

Van didn't you unearth this a ways back?
More...
Stoney, I got a decent position in VUZI at a average cost of $14 since March 4-5 tech collapse triple downed at $13. Is this another Corsair?
 
TrailerParkTed said:
Stoney, I got a decent position in VUZI at a average cost of $14 since March 4-5 tech collapse triple downed at $13. Is this another Corsair?
More...


This is a tough one. First off Congrats! That's really great news. Cathy Ark is in the stk now so the world is your oyster. When does it stop? Any real mews of Apple moving down the food chain with the glasses... That's kind of what got this extra run is that the mid range glasses appears not to attract Apple at this point.

At some point China steals the technology.... If they haven't already...

Considering VUZI's

Return on Assets(ttm) -29.59%
Return on Equity(ttm) -49.49%

I would be inclined to sell now.
 
stonedinvestor said:
This is a tough one. First off Congrats! That's really great news. Cathy Ark is in the stk now so the world is your oyster. When does it stop? Any real mews of Apple moving down the food chain with the glasses... That's kind of what got this extra run is that the mid range glasses appears not to attract Apple at this point.

At some point China steals the technology.... If they haven't already...

Considering VUZI's

Return on Assets(ttm) -29.59%
Return on Equity(ttm) -49.49%

I would be inclined to sell now.
More...
What if I sold covered calls? MYO is holding well too, bought more before earnings bringing average down on March 5th. That’s a razor thin play, spread is $.60 at volatile times. Nice picks Stoney! You and Van know how to sift through the wheat and chaff.
 
You must log in or register to reply here.
Back
Top